




# Third Quarter 2021 Business Update

November 16, 2021

PARIS: IPH.PA

NASDAQ: IPHA



# Disclaimer on Forward-Looking Information and Risk Factors



This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed.

This document contains forward-looking statements. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertainties, which could cause the Company’s actual results or financial condition to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF website ([www.amf-france.org](http://www.amf-france.org)) or on the Company’s website ([www.innate-pharma.com](http://www.innate-pharma.com)), and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2020, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. Such documents may not be necessarily up to date.

This document contains data pertaining to the Company’s potential markets and the industry and environment in which it operates. Some of this data comes from external sources that are recognized in the field or from Company’s estimates based on such sources.

This presentation discusses product candidates that are under clinical development and which have not yet been approved for marketing by the U.S. Food and Drug Administration or the European Medicines Agency. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied.

The information contained herein has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The Company is under no obligation to keep current the information contained in this presentation and any opinion expressed is subject to change without notice.

The Company shall not bear any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

This document and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares of the Company in any country.

# Speakers on Today's Call



**Mondher Mahjoubi, MD**  
*Chief Executive Officer  
Chairman of the Executive Board*



**Joyson Karakunnel, MD, MSc, FACP**  
*EVP, Chief Medical Officer*




**Yannis Morel, PhD**  
*EVP, Head of Business Development  
and Portfolio Strategy  
(Q&A)*



**Frédéric Lombard, MBA**  
*SVP, Chief Financial Officer  
(Q&A)*

# Our Robust Pipeline of Proprietary & Partnered Assets


Program	Target	Indication	Pre-Clinical	Phase 1	Phase 2	Phase 3	Status
<b>Lacutamab</b>	KIR3DL2	Sézary Syndrome	PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION)				Preliminary Phase 2 data expected 2022
		Mycosis Fungoides				PHASE 2	Early data presented Preliminary Phase 2 data expected 2022
		PTCL (combo with GemOx)				PHASE 2	Phase 2 start H2 2021
		PTCL (mono)	PHASE 1b				Phase 1 start H2 2021
<b>Monalizumab*</b>	NKG2A	Post-PDx HNSCC				PHASE 3	Phase 3 data expected 2022+*
		Head and Neck cancer				PHASE 2	Phase 2 data expected H2 2021
		Unres. Stg III/neoadj NSCLC				PHASE 1/2	Phase 3 planned – unresectable, Stg III NSCLC Phase 2 planned – neoadjuvant NSCLC
<b>Avdoralimab</b>	C5aR	BP				PHASE 2	Data expected 2022
<b>IPH5201*</b>	CD39	Cancer (solid tumors)	PHASE 1				Data expected 2022
<b>IPH5301</b>	CD73	Cancer (solid tumors)	PHASE 1				Phase 1 start H2 2021
 <b>ANKET™</b> <small>Antibody-based NK cell Engage Therapeutics</small>	IPH6101** (tri-specific CD123)		Pre-clinical				IPH6101 Phase 1 trial in planning IND-enabling studies
	IPH62* (tri-specific)						
	IPH64** (tri-specific)						
	IPH65 (tetra-specific)						
<b>Other preclinical</b>	IPH25*, IPH26* (Siglec-9), IPH43* (MICA/B ADC), IPH45		Pre-clinical				

GemOx: gemcitabine and oxaliplatin; PDx: anti-PD-1/L1; HNSCC: Head and Neck Squamous Cell Carcinoma; BP: Bullous Penphigoid; PTCL: Peripheral T Cell Lymphoma; IND: Investigational New Drug



## Drive near-term value with Lacutamab

- Encouraging preliminary data in MF KIR3DL2-expressing TELLOMAK cohort
- Announced data-driven clinical development plan for PTCL



## Advance our innovative R&D pipeline

- Sanofi advanced Innate's lead ANKET candidate, IPH6101/SAR443579; Phase 1 trial in planning



## Build sustainable business through partnerships

- Strong monalizumab collaboration with AstraZeneca
- Phase 3 in HNSCC underway
- Unresectable Stage III NSCLC Phase 3 planned



# Monalizumab Phase 2 Data from COAST trial

**COAST: An open-label, randomized, phase 2 platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC**


## Antitumour activity by investigator assessment (interim analysis; ITT population)

Antitumour activity	D (N=67)	D+O (N=60)	D+M (N=62)
<b>Confirmed ORR (95% CI),<sup>b</sup> %</b>	<b>17.9 (9.6, 29.2)</b>	<b>30.0 (18.8, 43.2)</b>	<b>35.5 (23.7, 48.7)</b>
[n]	[12]	[18]	[22]
<b>Confirmed + unconfirmed ORR (95% CI),<sup>b</sup> %</b>	<b>25.4 (15.5, 37.5)</b>	<b>38.3 (26.1, 51.8)</b>	<b>37.1 (25.2, 50.3)</b>
[n]	[17]	[23]	[23]
<b>ORR odds ratio (95% CI)<sup>a,b</sup></b>	–	<b>1.83 (0.80, 4.20)</b>	<b>1.77 (0.77, 4.11)</b>
<b>Objective responses by RECIST,<sup>a</sup> n (%)</b>			
CR	2 (3.0)	1 (1.7)	3 (4.8)
PR	15 (22.4)	22 (36.7)	20 (32.3)
SD	27 (40.3)	25 (41.7)	27 (43.5)
PD	15 (22.4)	7 (11.7)	7 (11.3)
NE	8 (11.9)	5 (8.3)	4 (6.5)
<b>DCR at 16 weeks (95% CI),<sup>a,c</sup> %</b>	<b>58.2 (45.5, 70.2)</b>	<b>81.7 (69.6, 90.5)</b>	<b>77.4 (65.0, 87.1)</b>
[n]	[39]	[49]	[48]
<b>Median DoR (95% CI),<sup>a</sup> months</b>	<b>NR (2.3, NA)</b>	<b>12.9 (6.7, NA)</b>	<b>NR (9.0, NA)</b>
Range	0.0+, 17.5+	0.0+, 16.9+	1.9+, 18.4+

Data cutoff: 17 May 2021 (median follow-up of 11.5 months; range, 0.4–23.4)  
<sup>a</sup>Confirmed and unconfirmed responses; <sup>b</sup>95% CI by Clopper-Pearson exact method; <sup>c</sup>DCR at 16 weeks = CR + PR + SD for ≥16 weeks  
 CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; NA, not applicable; NE, not evaluable; NR, not reached; ORR, objective response rate; PR, partial response; PD, progressive disease; SD, stable disease



## PFS by investigator assessment (interim analysis; ITT population)




Data cutoff: 17 May 2021 (median follow-up of 11.5 months; range, 0.4–23.4)  
<sup>a</sup>Interim analysis was performed when all patients had a 10-month minimum potential follow-up; Kaplan-Meier estimates for PFS, PFS rate and 95% CIs  
<sup>b</sup>PFS HR and 95% CI estimated by Cox regression model, stratified by histology (adenocarcinoma and non-adenocarcinoma)  
<sup>c</sup>Compared with the 67 and 64 patients in the D arm enrolled concurrently with patients in the D+O and D+M arms, respectively  
 CI, confidence interval; HR, hazard ratio; ITT, intention to treat; mPFS, median PFS; NE, not estimable; NR, not reached

Propensity analysis of durvalumab arms of COAST and PACIFIC Phase 3 trial using matched variables indicated worse prognostic patients recruited in COAST than PACIFIC


# Monalizumab: Early NSCLC development program underway

Phase 3 program to be initiated, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC



# Monalizumab: Head and Neck cancer

Innate's first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated HNSCC



# ANKET™: Innate's Proprietary NK Cell Engager Platform



**is a versatile, fit-for-purpose technology** that is creating **an entirely new class** of tri- and tetra-specific molecules to induce synthetic immunity against cancer




Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46



Provides proliferation and activation signals targeted to NK cells




Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models




# CD123 targeted IPH6101/SAR443579 Demonstrates Potent Antitumor Activity Against AML and Favorable Safety Profile



## IPH6101/SAR443579 kills AML cells resistant to ADCC



## IPH6101/SAR443579 induce CD123-expressing cell depletion in NHP with minor cytokine release





**The first NKp46/CD16-based NK Cell engager using ANKET  
Expected to enter phase 1 trial in AML and HR-MDS**






# Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors




## Solid tumor models





Vehicle



## Disseminated tumor models



Vehicle



Obinituzumab\*

Progressing towards IND enabling studies



# Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas



## Cutaneous T-Cell Lymphoma (CTCL)

## Peripheral T-Cell Lymphoma (PTCL)

### Phase 2 TELLOMAK Trial

#### Sezary Syndrome

**80-200 patients**

>90% KIR3DL2 expression

- Trial expanded (pivotal potential)
- Fast Track & PRIME Designation
- Preliminary data expected in 2022

#### Mycosis Fungoides

**2,200-4,400 patients**

~50% KIR3DL2 expression

- Advanced Cohort 2 to Stage 2 with earlier-than-expected efficacy signal
- 2 cohorts – KIR3DL2 expressing and non expressing
- Reported preliminary Stage 1 data at ICML – 35% ORR
- Preliminary data expected in 2022

#### Multi-trial Strategy From Relapsed to Frontline PTCL

**~18,000 patients**

~50% KIR3DL2 expression

- Initiate Monotherapy + combination with GemOX (LYSA) & SOC in relapsed setting in 2021
- Follow data into earlier lines (in combination with CHOP)

# Key Newsflow Over the Next 12+ Months

Q 4 2 0 2 1

## Data Readouts

- Monalizumab Cohort 3 Phase 2 combo HNSCC

## Clinical Progress

- Lacutamab r/r PTCL mono Phase 1b starting
- Lacutamab r/r PTCL combo Phase 2 starting (IST)
- IPH5301 (CD73) Phase 1 starting (IST)
- ANKET™ IPH6101/SAR443579 IND-enabling studies (Sanofi)

2 0 2 2

## Data Readouts

- Lacutamab Phase 2 MF data (preliminary)
- Lacutamab Phase 2 SS data (preliminary)
- Lacutamab Phase 1b PTCL data (preliminary)
- Avdoralimab BP Phase 2 data (IST)
- IPH5201 (CD39) Phase 1 data

## Clinical Progress


- Monalizumab unresect. Stg III Phase 3 start (AstraZeneca)
- Lacutamab PTCL 1L planning
- Proprietary ANKET™ progress towards IND

# Early R&D focus to drive value through later stage partnerships



## Drive near-term value with Lacutamab

- TELLOMAK read-out with MF in 2021 and preliminary data for MF and SS in 2022
- Initiating monotherapy and combination PTCL studies in H2 2021



## Advance our innovative R&D pipeline

- Advancing proprietary NK cell-targeted platform and portfolio
- Sanofi IPH6101/SAR443579 Phase 1 clinical trial in planning



## Build sustainable business through partnerships

- Strong monalizumab collaboration with AstraZeneca, currently in Phase 3
- Cash position of €141.8 million\* as of September 30, 2021 with runway until at least end of 2022

Harnessing innate immunity to create novel therapeutics in areas of unmet medical need



# Questions and Answers